Moneycontrol PRO
Upcoming Webinar:Moneycontrol Pro in association with Quants League Sep'21 Edition brings to you to 5-Days Live Algorithmic Options Trading Virtual Conference. Register Now!
you are here: HomeNewscoronavirus

COVID-19 Vaccine: Results of Covaxin's trials on children expected by September, says AIIMS Chief Dr Randeep Guleria

"The vaccines for children should come out now because trials in India are already there in the vaccines which are available in India, the Bharat Biotech trial is in the final phase by September we will have the data," Dr Randeep Guleria said.

July 24, 2021 / 06:48 PM IST
AIIMS Director Dr Randeep Guleria (Image Source: ANI)

AIIMS Director Dr Randeep Guleria (Image Source: ANI)

Dr Randeep Guleria, Director of All India Institute of Medical Science (AIIMS) has informed that the trials of Bharat Biotech's Covaxin on children are underway and the results are expected by September.

"The vaccines for children should come out now because trials in India are already there in the vaccines which are available in India, the Bharat Biotech trial is in the final phase by September we will have the data," Dr Guleria told ANI.

He further added that by September vaccines should be available for children post which schools should start reopening in a graded manner.

Covaxin's trials on children are being conducted in three phases by segregating the children into categories according to their age. The first trial was in the age group of 12-18 years and the second was 6-12 years. Trails for children in the age group of 2-6 years is currently underway.

Other than Bharath Biotech, Zydus Cadila's vaccine, ZyCov-D was also put to trials on children between the age group of 12-18. This data has been included as well, while the company sought Emergency Use Authorization (EUA) from the Drugs Controller General of India (DGCI), said Dr Guleria.


COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more

Zydus Cadila had on July 1 requested EUA for its vaccine- a three-dose shot which is the world's first plasmid DNA vaccine. However, sources told ANI that it will take a few more days before EUA is granted.

Earlier today, Bharat Biotech said it had terminated its memorandum of understanding (MOU) dated November 24, 2020, with Brazil-based Precisa Medicamentos (Precisa) and Envixia Pharmaceuticals.

The vaccine manufacturer said it had entered into MOU with Precisa and Envixia to introduce Covaxin in Brazil.

However, Bharat Biotech said it will continue to work diligently with ANVISA, the Brazilian drug regulatory body, to complete the regulatory approval process for Covaxin
Moneycontrol News
first published: Jul 24, 2021 06:48 pm

stay updated

Get Daily News on your Browser
ISO 27001 - BSI Assurance Mark